Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Mirae secures $5.4M in funding led by Oxford Science Enterprises to expand access to world-class specialty care for autoimmune disease treatment.
PRIVATEJul 28, 2026•1 day ago
Amount Raised
$5.4 Million
Round Type
Venture - Series Unknown
New YorkBiotechnologyHealth CareArtificial IntelligenceMedical
Investors
Oxford Science Enterprises
Description
Mirae announced $5.4 million in funding, which will help the company enhance its AI-driven continuous care platform for complex chronic conditions. The funding is aimed at improving patient support with a structured view of disease management. Focused on inflammatory bowel disease, Mirae's platform leverages real-world data for better treatment decisions. The investment will facilitate ongoing model development and validation within a leading U.S
Company Information
Company
Mirae
Location
New York, New York, United States
About
Mirae is an AI-driven continuous care platform focused on autoimmune disease and complex chronic conditions. The platform captures patient experiences between visits and converts them into actionable insights that clinicians can use for informed treatment decisions. Initially targeting inflammatory bowel disease (IBD), Mirae aims to provide ongoing access to real-world patient data to enhance care. By combining patient-reported data with clinical context, the company aspires to improve outcomes and access to world-class care.
New YorkBiotechnologyHealth CareArtificial IntelligenceMedical